EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance
Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2017.0151
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2017
Authors
Publisher
Harborside Press, LLC